Merz Pharmaceuticals Articles
Briefs: Bidding war for Obagi escalates, as Valeant ups offer; AstraZeneca plans to sue Actavis
3 April 2013
Good news from CHMP for Astellas, Savient, Bayer and Abbott, but not for Lundbeck and Merz
22 October 2012
FDA OKs Merz' Xeomin for cervical dystonia and blepharospasm; and two generics for Sagent
3 August 2010
Forest/Merz settle with Mylan and others of generic Namenda; Impax’ generic Opana cleared in USA
23 July 2010
Showing 1-7 of 7 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
